Table 4. The main results of meta-analysis of the association between the GNB3 C825T polymorphism and hypertension.
| T allele vs. C allele (allelic model) | TT+CT vs. CC (dominant model) | TT vs. CT+CC (recessive model) | |||||||
| Study group | OR (95%CI) | p | I 2 | OR (95%CI) | p | I2 | OR (95%CI) | p | I2 |
| Overall | 1.07 (1.01,1.13) | 0.02 | 71% | 1.08 (0.98,1.81) | 0.11 | 74% | 1.05 (0.97,1.14) | 0.23 | 58% |
| Excluding outlier studies | 1.03 (1.00,1.06) | 0.06 | 0% | 1.05 (1.00,1.11) | 0.03 | 0% | 1.00 (0.95,1.05) | 0.92 | 0% |
| Male | 0.93 (0.79,1.11) | 0.43 | 71% | 1.01 (0.80,1.28) | 0.92 | 59% | 1.02 (0.87,1.18) | 0.82 | 45% |
| Female | 1.11 (0.99,1.24) | 0.08 | 0% | 1.05 (0.90,1.24) | 0.53 | 0% | 1.35 (1.07,1.70) | 0.01 | 0% |
| Caucasian | 1.18 (1.00,1.39) | 0.05 | 76% | 1.22 (0.97,1.54) | 0.09 | 79% | 1.10 (0.90,1.34) | 0.36 | 20% |
| Asian | 1.05 (0.99,1.11) | 0.12 | 68% | 1.05 (0.94,1.16) | 0.39 | 72% | 1.04 (0.95,1.15) | 0.37 | 63% |
| HWE | |||||||||
| Y | 1.03 (0.97,1.10) | 0.32 | 68% | 1.04 (0.96,1.14) | 0.34 | 58% | 1.02 (0.93,1.11) | 0.71 | 52% |
| N | 1.18 (1.06,1.33) | 0.004 | 70% | 1.13 (0.86,1.48) | 0.39 | 88% | 1.19 (0.96,1.47) | 0.11 | 71% |
| Source of control | |||||||||
| HB | 1.07 (0.99,1.16) | 0.07 | 0% | 1.15 (0.92,1.44) | 0.23 | 35% | 1.11 (0.89,1.39) | 0.34 | 17% |
| PB | 1.07 (1.00,1.13) | 0.05 | 74% | 1.07 (0.97,1.18) | 0.21 | 76% | 1.04 (0.96,1.14) | 0.34 | 62% |
| Normal population* | 1.04 (0.97,1.12) | 0.25 | 69% | 1.05 (0.96,1.16) | 0.30 | 61% | 1.03 (0.93,1.14) | 0.57 | 59% |
| Score≥8 | 1.08 (1.01,1.16) | 0.03 | 76% | 1.07 (0.97,1.18) | 0.20 | 75% | 1.03 (0.97,1.11) | 0.34 | 32% |
p, a p-value of combined effect; CI, confidence interval;
*
, We conducted the analyses by limiting the studies according to the HWE and excluding those that included myocardial infarction, obesity, or diabetes mellitus in the cases or controls.